TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35943226

Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PDL
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CO2 + PDL
Number of subjects: 25
Study: 34398868

Group type: EXPERIMENTAL
Intervention: DePuy Synthes Rapidsorb Fixation System
Number of subjects: 325
Study: 35457616

Group type: EXPERIMENTAL
Intervention: Biography and Life Storybook (BLSB) intervention, comprising eight nurse-facilitated structured sessions over three months and usual daily activities.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Routine activities (Control group).
Number of subjects: 74
Study: 33594692

Group type: EXPERIMENTAL
Intervention: CHECK program services
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1322
Study: 36468835

Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd: YAG laser 1064 nm
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intralesional botulinum toxin type-A (BTX-A)
Number of subjects: 30
Study: 34420987

Group type: EXPERIMENTAL
Intervention: Neuroplasticity-based computerized cognitive remediation program (Brain Fitness Program), 40 one-hour sessions
Number of subjects: 48
Study: 32406100

Group type: EXPERIMENTAL
Intervention: Low fluoroscopy group (LFG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional fluoroscopy group (CFG)
Number of subjects: 50
Study: 35028764

Group type: EXPERIMENTAL
Intervention: Low-level light therapy with light-emitting diodes (LED) applied on two acupoints (CV4 and CV6)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional treatment with oral Marvelon, 30 µg of ethinyl estradiol and 150 µg of desogestrel (DSG/EE)
Number of subjects: 156

Group type: COMPARATOR
Intervention: DSG/EE group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 156
Study: 34457024

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no hypnosis)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (Hypnosis and Control)
Number of subjects: 31
Study: 35413919

Group type: EXPERIMENTAL
Intervention: PACE
Number of subjects: 344

Group type: COMPARATOR
Intervention: Adapted PACE
Number of subjects: 344
Study: 33355814

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection at lateral sites of internal sphincter muscle (group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection at anterior and posterior regions (group 2)
Number of subjects: 80
Study: 36279134

Group type: EXPERIMENTAL
Intervention: Guideline-based primary prophylactic colony-stimulating factor standing order system
Number of subjects: 2946

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2946
Study: 33625621

Group type: EXPERIMENTAL
Intervention: SWITCH TO TMP‐SMX group
Number of subjects: 70

Group type: COMPARATOR
Intervention: NO SWITCH TO TMP‐SMX group
Number of subjects: 70
Study: 35786077

Group type: EXPERIMENTAL
Intervention: Errorless learning and RehaGoal App‐based dressing practice (seven sessions of 45 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard therapy in the rehab unit
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Errorless learning and RehaGoal App‐based dressing practice
Number of subjects: 24
Study: 33539228

Group type: EXPERIMENTAL
Intervention: Laptop note-taking
Number of subjects: 142

Group type: COMPARATOR
Intervention: Longhand note-taking
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Higher word count
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Higher verbatim overlap
Number of subjects: 142
Study: 32282739

Group type: COMPARATOR
Intervention: Control group: undiluted contrast agent (2 ml/kg, upper limit 50 ml) injected 1 time.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Research group: first bolus of 20% diluted contrast agent (1 ml/kg, upper limit 25 ml) followed by undiluted contrast agent (1 ml/kg, upper limit 25 ml).
Number of subjects: 100
Study: 34633508

Group type: EXPERIMENTAL
Intervention: Warm environmental temperature (31 °C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control environmental temperature (21 °C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AS group
Number of subjects: 20

Group type: COMPARATOR
Intervention: AA group
Number of subjects: 20
Study: 33784280

Group type: EXPERIMENTAL
Intervention: Immediate oral feeding (8 hours after management)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Early oral feeding (48 hours after management)
Number of subjects: 59
Study: 35095912

Group type: EXPERIMENTAL
Intervention: Basal diet with 500 mg/kg of Gallic Acid + transportation (TS+GA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Basal diet + transportation (TS)
Number of subjects: 19
Study: 32007694

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (40 mg/d for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 34269807

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (enhanced barrier precautions, chlorhexidine bathing, MDRO surveillance, environmental cleaning education and feedback, hand hygiene promotion, health care worker education and feedback)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (standard care practices)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 245
Study: 36388236

Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (PTNS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 16
Study: 32001614

Group type: EXPERIMENTAL
Intervention: Intensive glycemic management
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Optimal glycemic control after a first event
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: HbA1c (per 1% higher)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: HbA1c (for subsequent events)
Number of subjects: 1441
Study: 34478173

Group type: EXPERIMENTAL
Intervention: NGT-G
Number of subjects: 223

Group type: COMPARATOR
Intervention: LT
Number of subjects: 223
Study: 34152828

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg once daily (with a possible dose increase to 400 mg)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222
Study: 32634571

Group type: EXPERIMENTAL
Intervention: CBD in powder form
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CBD in sesame oil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CBD in self-nano-emulsifying drug delivery system (SNEDDS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lipid-based vehicles (sesame oil and SNEDDS)
Number of subjects: 12
Study: 35267110

Group type: EXPERIMENTAL
Intervention: SWEEPS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PIPS
Number of subjects: 200

Group type: COMPARATOR
Intervention: PUI
Number of subjects: 200

Group type: COMPARATOR
Intervention: sonic (EDDY)
Number of subjects: 200

Group type: COMPARATOR
Intervention: MDA
Number of subjects: 200
Study: 33990435

Group type: EXPERIMENTAL
Intervention: Catheter-directed cervical interlaminar epidural steroid injection with triamcinolone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cervical transforaminal steroid injection with dexamethasone
Number of subjects: 117
Study: 32799709

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Baseline HII ≤0.5
Number of subjects: 517
Study: 35276993

Group type: EXPERIMENTAL
Intervention: Concept IF with large, milk phospholipid-coated lipid droplets and prebiotic mixture (scGOS/lcFOS 9:1)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control IF with prebiotics
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control IF without prebiotics
Number of subjects: 92
Study: 34607784

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using Ga Al As laser with a wavelength of 810nm and a power of 100 mW, applied on days 0, 3, 30, and 60 for 18 seconds each time.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intra-oral LED device with a wavelength of 640nm and a power density of 40 mW/cm2, used 5 minutes per day.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment using a coated light cure device, following the same protocol as the laser group.
Number of subjects: 60
Study: 36429935

Group type: EXPERIMENTAL
Intervention: Combined training program (postural control and fine motor skills exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching program (Control group)
Number of subjects: 0
Study: 33844996

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 µg per actuation, 2 inhalations twice a day until symptom resolution)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 146
Study: 34378493

Group type: EXPERIMENTAL
Intervention: One-legged high-loading intervention for 3 months using a mobile set-up
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control leg (contralateral/untrained leg)
Number of subjects: 12
Study: 32432684

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 5711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5711
Study: 32003649

Group type: EXPERIMENTAL
Intervention: modified alternate‐day fasting diet
Number of subjects: 80
Study: 36038833

Group type: EXPERIMENTAL
Intervention: Fremanezumab (quarterly)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Fremanezumab (monthly)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Fremanezumab (quarterly and monthly)
Number of subjects: 1500
Study: 34578959

Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention
Number of subjects: 468
Study: 32473275

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 36224641

Group type: EXPERIMENTAL
Intervention: Intermittent fasting 5:2
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 34668352

Group type: EXPERIMENTAL
Intervention: No-Touch Radiofrequency Ablation (NT-RFA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional Radiofrequency Ablation (RFA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: RFA type (NT-RFA vs Conventional RFA)
Number of subjects: 73
Study: 35727800

Group type: EXPERIMENTAL
Intervention: Growth Assessment Protocol (GAP)
Number of subjects: 24096

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24096

Group type: EXPERIMENTAL
Intervention: GAP
Number of subjects: 24096
Study: 32654098

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, chloroquine, or azithromycin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: QTc > 500 ms or an increase of 60 ms
Number of subjects: 105
Study: 35286860

Group type: EXPERIMENTAL
Intervention: Inhaled 7% hypertonic saline
Number of subjects: 116

Group type: COMPARATOR
Intervention: 0.9% isotonic saline
Number of subjects: 116

Group type: COMPARATOR
Intervention: Comparison of hypertonic saline vs isotonic saline
Number of subjects: 116
Study: 33734828

Group type: EXPERIMENTAL
Intervention: 80 mg atomoxetine + 5 mg solifenacin succinate (ato-sol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 80 mg atomoxetine + 2 mg biperiden hydrochloride (ato-bip)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 35781439

Group type: EXPERIMENTAL
Intervention: Qmix
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chitosan
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: EDTA/sodium hypochlorite
Number of subjects: 90

Group type: COMPARATOR
Intervention: Irradiated group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonirradiated group
Number of subjects: 90
Study: 34006565

Group type: EXPERIMENTAL
Intervention: Metformin (up to 2,000 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss
Number of subjects: 121

Group type: COMPARATOR
Intervention: Self-directed care (control)
Number of subjects: 121
Study: 32532790

Group type: EXPERIMENTAL
Intervention: BR induction followed by 2-year rituximab maintenance (BR-R)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: BR with bortezomib and rituximab maintenance (BVR-R)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: BR followed by lenalidomide (1 year) with rituximab maintenance (BR-LR)
Number of subjects: 289

Group type: COMPARATOR
Intervention: BR-R
Number of subjects: 289

Group type: COMPARATOR
Intervention: BVR-R
Number of subjects: 289

Group type: COMPARATOR
Intervention: BR-LR
Number of subjects: 289
Study: 35301854

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Number of subjects: 53
Study: 36403205

Group type: EXPERIMENTAL
Intervention: Closed-loop automated oxygen control (CLAC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard care (manual oxygen control)
Number of subjects: 16
Study: 34210154

Group type: EXPERIMENTAL
Intervention: Genetically increased TSH
Number of subjects: 134641

Group type: EXPERIMENTAL
Intervention: Genetically increased fT4
Number of subjects: 134641

Group type: EXPERIMENTAL
Intervention: Genetically predicted hyperthyroidism
Number of subjects: 134641

Group type: EXPERIMENTAL
Intervention: Genetically predicted hypothyroidism
Number of subjects: 134641
Study: 35651299

Group type: EXPERIMENTAL
Intervention: Clemastine fumarate injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 100
Study: 34351436

Group type: EXPERIMENTAL
Intervention: GX301 cancer vaccine regimen 1 (eight administrations)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: GX301 cancer vaccine regimen 2 (four administrations)
Number of subjects: 98

Group type: COMPARATOR
Intervention: GX301 cancer vaccine regimen 3 (two administrations)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Overall survival across all regimens
Number of subjects: 98
Study: 36173326

Group type: EXPERIMENTAL
Intervention: Alternating bilateral training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unilateral training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alternating bilateral training (specifically for left hemiparesis)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unilateral training (specifically for left hemiparesis)
Number of subjects: 24
Study: 34241801

Group type: EXPERIMENTAL
Intervention: Buxue Yimu Pills (BYP, 24 g/d)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FS Tablets, 0.9 g/d)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of BYP and FS (BYP 24 g/d plus FS Tablets 0.9 g/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 32711435

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement program
Number of subjects: 130

Group type: COMPARATOR
Intervention: Knowledge and usual care by health personnel
Number of subjects: 130
Study: 34933917

Group type: EXPERIMENTAL
Intervention: Educational intervention guided by a cognitive map (the 'empathy circle') with motivational texts.
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 221
Study: 33847977

Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 216

Group type: COMPARATOR
Intervention: hCG
Number of subjects: 216
Study: 32682494

Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir (300 mg and 120 mg, three tablets daily for 8 weeks)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir (300 mg and 120 mg, three tablets daily for 12 weeks)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir
Number of subjects: 546
Study: 36353338

Group type: EXPERIMENTAL
Intervention: Pilates training + dill supplementation (PDG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pilates training + placebo (PPG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dill supplementation (DG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 45
Study: 34488847

Group type: EXPERIMENTAL
Intervention: EMDR therapy (two sessions between 14 and 35 days postpartum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 0
Study: 33186304

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Video games (tablet with videogame applications)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cartoon ('Şüko Is Being Operated')
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 138
Study: 35500465

Group type: EXPERIMENTAL
Intervention: Deflazacort 0.45 mg/kg/d
Number of subjects: 97

Group type: COMPARATOR
Intervention: Deflazacort 0.9 mg/kg/d
Number of subjects: 97
Study: 33833945

Group type: EXPERIMENTAL
Intervention: Telemedicine technology-based program with comprehensive counseling and biweekly remote support for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group receiving routine care with individual single-session counseling
Number of subjects: 100
Study: 34293934

Group type: EXPERIMENTAL
Intervention: RISE intervention (8-week psychoeducational group program)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 75
Study: 33999753

Group type: EXPERIMENTAL
Intervention: Forsvall needle prototype
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard Tru-Cut needle (BARD 18 G)
Number of subjects: 10
Study: 32794483

Group type: EXPERIMENTAL
Intervention: Closed reduction and internal fixation with dynamic hip screw (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Closed reduction and internal fixation by proximal femoral nail (Group B)
Number of subjects: 90
Study: 33034748

Group type: EXPERIMENTAL
Intervention: Radiomics score combined with ACR guidelines (Rad_5%)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Radiomics score combined with ATA guidelines (Rad_5%)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Radiomics score alone
Number of subjects: 1609
Study: 32716700

Group type: EXPERIMENTAL
Intervention: FDA-approved vaccines with postapproval safety-related label modifications
Number of subjects: 57

Group type: COMPARATOR
Intervention: FDA-approved vaccines without postapproval safety-related label modifications
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Postmarketing surveillance data
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Safety issues identified through postmarketing surveillance
Number of subjects: 57
Study: 33967252

Group type: EXPERIMENTAL
Intervention: +2.00 D add multifocal lenses
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: +3.00 D add multifocal lenses
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: +4.00 D add multifocal lenses
Number of subjects: 11

Group type: COMPARATOR
Intervention: Single-vision lenses
Number of subjects: 11
Study: 33427173

Group type: EXPERIMENTAL
Intervention: Higher caregiving quality at age 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Never-institutionalized children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ever-institutionalized children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foster care placement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged deprivation
Number of subjects: 0
Study: 34705137

Group type: EXPERIMENTAL
Intervention: Early Botulinum toxin injection (50 U) administered 1 week before surgery
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Early Botulinum toxin injection
Number of subjects: 62
Study: 32429708

Group type: EXPERIMENTAL
Intervention: Half-day CBTI workshop
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Self-help Internet-delivered CBTI
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Half-day SHE workshop
Number of subjects: 210
Study: 33306999

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Tube
Number of subjects: 419

Group type: COMPARATOR
Intervention: IRIS Registry
Number of subjects: 419

Group type: COMPARATOR
Intervention: RCT
Number of subjects: 419
Study: 35732572

Group type: EXPERIMENTAL
Intervention: Incontinence training with urotherapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Typically developing children (control group)
Number of subjects: 21
Study: 32493125

Group type: EXPERIMENTAL
Intervention: Recruitment strategies and decision making
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Importance of recruiters
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Research governance demands
Number of subjects: 20
Study: 34328630

Group type: EXPERIMENTAL
Intervention: 90 mcg ropeginterferon alfa-2b
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 180 mcg ropeginterferon alfa-2b
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 270 mcg ropeginterferon alfa-2b
Number of subjects: 40

Group type: COMPARATOR
Intervention: peg-IFN alfa-2a
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b (all doses)
Number of subjects: 40
Study: 33975525

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 36181085

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (target train‐of‐four 0 and posttetanic count ≥ 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (target train‐of‐four count 1‐3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 72

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 72
Study: 32098542

Group type: EXPERIMENTAL
Intervention: Local vibrations (100 Hz)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 10
Study: 33033021

Group type: COMPARATOR
Intervention: Standard enteral feeding formula (1.5 kcal/mL, 54% carbohydrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate isocaloric enteral feeding formula (1.5 kcal/mL, 28% carbohydrate)
Number of subjects: 0
Study: 36660970

Group type: EXPERIMENTAL
Intervention: Probiotics and Zinc (Group 4)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Probiotics (Group 2)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Zinc (Group 3)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Dietary recommendations (Control Group 1)
Number of subjects: 132